Peranan Probiotik dalam Penanganan Infeksi COVID-19
DOI:
https://doi.org/10.55175/cdk.v48i5.71Keywords:
Antiinflamasi, COVID-19, probiotikAbstract
Infeksi COVID-19 yang pertama kali ditemukan di Wuhan, Cina, pada akhir Desember 2019 telah mengenai lebih dari 60 juta penduduk dan merenggut nyawa sekitar 1,4 juta jiwa. Hingga saat ini belum ada pengobatan untuk infeksi virus SARS-CoV-2 ini. Probiotik merupakan salah satu agen yang dikenal luas, telah terbukti memiliki efek antiinflamasi, antivirus, terlibat dalam pembentukan antibodi, dan terakhir terlibat dalam aktivasi ACE-2 sebagai reseptor tempat kerja virus SARS-CoV-2. Penggunaan probiotik untuk mengatasi infeksi COVID-19 masih diteliti.
COVID-19 infection, firstly detected at the end of December 2019 in Wuhan, China, has affected more than 60 million people worldwide with 1,4 million deaths. Until now there is no treatment for this disease. Probiotic has proven to have an antiinflamatory, antivirus activites, involved in the antibody formation, and can be involved in ACE-2 receptor activation as the main receptor of SARS-CoV-2 virus. Many ongoing researches investigate the use probiotics in COVID-19 management.
Downloads
References
Akour A. Probiotics and COVID-19: Is there any link? Lett Appl Microbiol. 2020;71:1 – 12
Olaimat A, Aolymat I, Al-Holy M, Ayyash M, Ghoush MA, Al-Nabulsi AA, et al. The potential application of probiotics and prebiotics for the prevention and treatment of COVID-19. Npj Science of Food. 2020;4(17):1 – 7
Liu M, Zhu H, He Y, Zhu Y, Hu X, Zeng Y. Probiotics for treating Novel Coronavirus with diarrhea: A protocol for systemic review and meta analysis. Medicine 2020;99(38):1 – 4
Lingeswaran M, Goyal T, Ghosh R, Suri S, Mitra P, Sharma P. Inflammation, immunity and immunogenetics in COVID-19: A narrative review. Ind J Clin Biochem. 2020;35(3):260–73
Soy M, Keser G, Atagunduz P, Tabak F, Astagunduz I, Kayhan S. Cytokine storm in COVID-19: Pathogenesis and overview of anti inflammatory agents used in treatment. Clin Rheumatol. 2020;1 – 10
Ali MJ, Hanif M, Haider MA, Ahmed MU, Sundas FNU, Hirani A, et al. Treatment options for COVID-19: A review. Front Med. 2020;7(480):1–10
Lescheid DW. Probiotics as regulators of inflammation: A review. Functional Foods in Health and Disease 2014;4 (7):299–311
Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Front Microbiol. 2015;6(1085):1–14
Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharmoceut Analysis. 2020;10:102-8
Merad M, Martin JC. Pathological inflammation in patients with COVID-19: A key role for monocytes and macrophages. Nature Rev Immunol. 2020;20:356–62
Lucena TMC, Santos AFS, Lima BR, Borborema MEA, Silva JA. Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metabolic Syndrome. 2020;14:597-600
Gogineni VK, Morrow LE, Gregory PJ, Malesker MA. Probiotics: History and evolution. J Anc Dis Prev Rem. 2013;1(2):1 – 7
Sunaryanto R, Martius E, Marwoto B. Uji kemampuan Lactobacillus casei sebagai agensia probiotik. J Bioteknol Biosains Indon. 2014;1(1):9 – 14
Thammarutwasik P, Hongpattarakere T, Chantachum S, Kijroongrojana K, Itharat A, Reanmongkol W, et al. Prebiotics – A review. Songklanakarin J Sci Technol.2009;31(4):401–8
Bermudez-Brito M, Plaza-Diaz J, Munoz-Quezada S, Gomez-Llorente C, Gil A. Probiotic mechanisms of action. Ann Nutr Metab. 2012;61:160–74
Dumas A, Bernard L, Poquet Y, Lugo-Villarino G, Neyrolles O. The role of the lung microbiota and the gut-lung axis in respiratory infectious diseases. Microbioly 2018;20:1 – 9
Enaud R, Prevel R, Ciario E, Beaufils F, Wieers G, Guery B, et al. The gut-lung axis in health and respiratory diseases: A place for inter-organ and inter-kingdom crosstalks. Front Cell Infect Microbiol. 2020;10(9):1–11
Pourhossein M, Moravejolahkami AR. Probiotics in viral infections, with a focus on COVID-19: A systematic review. Isfahan University of Medical Sciences [Internet]. 2020:1 – 10. Available from: https://www.researchgate.net/publication/341362491_Probiotics_in_viral_infections_with_a_focus_on_COVID-19_A_Systematic_Review
Xu K, Cai H, Shen Y, Ni Q, Chen Y, Hu, S, et al. Management of corona virus disease-19 (C0VID-19): the Zhejiang experience. J Zhejiang University. 2020;49(1):0-0
Feng Z, Wang Y, Qi W. The small intestine, an underestimated site of SARS-CoV2 infection: From red queen effect to probiotics. Preprints [Internet]. 2020. Available from: https://www.preprints.org/manuscript/202003.0161/v1
Kimmel M, Keller D, Farmer S, Warrino D. A controlled clinical trial to evaluate the effect of GanedenBC (30) on immunological markers. Methods and Findings in Experiment Clin Pharmaco. 2020;32(2):129-32
Tian Z, Yang L, Li P, Xiao Y, Peng J, Wang X. The inflammation regulation effects of Enterococcus faecium HDRsEf1 on human enterocyte-like HT-29 cells. Animal Cells and Systems. 2016;20(2):70-6
Oh NS, Joung JY, Lee JY, Kim Y. Probiotic and anti-inflammatory potential of Lactobaccillus rhamnosus 4B15 and Lactobacillus gasseri 4M13 isolated from infant feces. PLoS One 2018;13: e0192021
Nagai T, Makino S, Ikegami S, Itoh H, Yamada H. Effects of oral administration of yogurt fermented with Lactobacillus delbrueckii ssp. Bulgaricus OLL1073R-1 and its exopolysaccharides against influenza virus infection in mice. Internat. Immunopharmacol. 2011;11(12):2246-50
Maeda N, Nakamura R, Hirose Y, Murosaki S, Yamamoto Y, Kase T, et al. Oral administration of heat-killed Lactobacillus plantarum L-137 enhances protection against influenza virus infection by stimulation of type I interferon production in mice. Internat Immunopharmacol. 2009;9(9):1122-5
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Cermin Dunia Kedokteran
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
